Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Luděk Bouchner"'
Autor:
Barbora Pipek, Dana Ďuricová, Katarína Mitrová, Martin Bortlík, Luděk Bouchner, Jan Březina, Tomáš Douda, Tomáš Drašar, Pavel Drastich, Přemysl Falt, Pavel Klvaňa, Pavel Kohout, Václav Leksa, Aleš Novotný, Pavel Svoboda, Jan Škorpík, Jan Ulbrych, Marek Veinfurt, Blanka Zbořilová, Milan Lukáš
Publikováno v:
Gastroenterologie a hepatologie. 76:46-54
Background: Inflammatory bowel disease (IBD) is mostly diagnosed in young women of fertile age, and a significant number of patients become pregnant while they have the disease. The remission of the illness, which is often achieved by intensive anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8852064299bca70a6b6fd73ee66aa6fa
https://doi.org/10.48095/ccgh202246
https://doi.org/10.48095/ccgh202246
Autor:
Martin Wasserbauer, Lucie Bartůsková, Pavel Drastich, Luděk Bouchner, Pavel Svoboda, Michal Konečný, František Pešek, Jana Koželuhová, Marek Benes, Pavel Wohl, Zdena Zádorová, Tomáš Vaňásek, Martin Pešta, Julius Spicak, Aleš Novotný, Přemysl Falt, Radan Keil, Jan Hajer, Martina Bojková
Publikováno v:
Scandinavian Journal of Gastroenterology
Objective: The infliximab biosimilar CT-P13 (Remsima®, Inflectra®) was approved in Europe for the treatment of inflammatory bowel disease (IBD) based on extrapolation of data from patients with rheumatic disease. Because there are limited published
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa17d5f752f0b711d6b7c0a096ea16cb
https://pubmed.ncbi.nlm.nih.gov/27002981
https://pubmed.ncbi.nlm.nih.gov/27002981
Autor:
Katarina Mitrova, Barbora Pipek, Martin Bortlik, Ludek Bouchner, Jan Brezina, Tomas Douda, Tomas Drasar, Pavel Drastich, Premysl Falt, Pavel Klvana, Vaclav Leksa, Ales Novotny, Pavel Svoboda, Jan Skorpik, Jan Ulbrych, Marek Veinfurt, Blanka Zborilova, Milan Lukas, Dana Duricova
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: Vedolizumab demonstrated different placental pharmacokinetics than other immunoglobulin G1 antibodies, leading to lower drug levels in cord blood in contrast to maternal blood at the time of delivery. The placental transfer of ustekinumab
Externí odkaz:
https://doaj.org/article/66e3c88cc9384a3790d80746cc08cc2d